24.60EUR+0.82%Mkt Cap: 1.96B $P/E: 19.843d ago
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compoundi…
Industry Peers
Drug Manufacturers - Specialty & Genericvs Drug Manufacturers - Specialty & Generic
P/E
Avg
P/B
Pricier
Div Yield
Avg
1M Perf
Avg
Indicators:|
Key Statistics
Company
Market Cap1.96B $
Enterprise Value2.23B $
Revenue (TTM)1.03B $
Gross Profit469.57M $
Net Income (TTM)98.93M $
Revenue/Share14.16 USD
Last Price24.60 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees4.2K
CountryBE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINBE0003874915
Valuation
P/E (Trailing)19.84
P/E (Forward)14.55
PEG15.84
EV/EBITDA12.29
EV/Revenue2.16
P/S1.86
P/B3.20
EPS (TTM)1.24
EPS (Forward)1.66
52W Range
19.2488% of range25.30
52W High25.30 EUR
52W Low19.24 EUR
Profitability
Gross Margin45.37%
Oper. Margin15.08%
EBITDA Margin17.55%
Profit Margin9.56%
ROE16.50%
ROA7.32%
Growth
Revenue Growth7.60%
Earnings Growth12.70%
Cash Flow & Leverage
Operating CF168.76M $
CapEx (TTM)33.27M $
FCF Margin8.77%
FCF Yield4.63%
Net Debt308.95M $
Net Debt/EBITDA1.70
Balance Sheet
Debt/Equity0.85
Current Ratio2.11
Quick Ratio1.39
Book Value/Sh7.531 EUR
Cash/Share2.525 EUR
Dividends
Fwd Div Rate0.4000 EUR
Trail. Div Rate0.4000 EUR
Div. Yield1.68%
5Y Avg Yield1.46%
Payout Ratio28.23%
Ex-Div DateMay 18, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)28.25 EUR
Upside (mean)+14.8%
Target Range27.00 EUR – 30.00 EUR
€27.00+14.8% to mean€30.00
# Analysts6
Ownership
Shares Out.73.35M
Float65.76M
Insiders0.30%
Institutions69.97%
Technical
SMA 5024.14 (+1.9%)
SMA 20022.12 (+11.2%)
Beta0.38
S&P 52W Chg20.05%
Avg Vol (30d)88.67K
Avg Vol (10d)75.56K
Technical Indicators
RSI (14)57.7
MACD0.0503
MACD Signal0.0154
MACD Hist.+0.0349
BB Upper24.79 EUR
BB Middle24.15 EUR
BB Lower23.52 EUR
BB Width5.27%
ATR (14)0.4059 EUR
Vol Ratio (20d)0.65x